Innovating CAR Engineering: Creative Biolabs' Customized Solutions for Targeted Cell Therapy Innovation

Creative Biolabs has a professional platform that provides customized CAR construction and design, meeting diverse needs of CAR-T cell therapy research.

SHIRLEY, NY, UNITED STATES, July 7, 2025 /EINPresswire.com/ -- As worldwide demands for next-generation immunotherapies continue to grow, Creative Biolabs is delighted to reaffirm its leadership in CAR-T therapy development. With its robust suite of platforms and services, Creative Biolabs' one-stop-shop CAR-T therapy development platform is committed to making every step of the therapeutic pipeline, from antigen discovery and CAR design through in vitro/in vivo validation and IND-enabling studies, more efficient.

Smart™ CAR design & construction service of Creative Biolabs permits the preparation of highly personalized CAR constructs, including dual CARs, TriCARs, and logic-gated CARs. These new-generation formats are engineered to enhance specificity, reduce off-target toxicity, and counteract tumor evasion mechanisms—the main limitations in both hematologic malignancies and solid tumors.

"Our mission is to simplify the complicated CAR-T development process," said one scientist at this company. "Having design, validation, and manufacturing all in one place, we allow our partners to speed up timelines without sacrificing quality or innovation."

In order to address the increasing need for hematologic malignancies, Creative Biolabs provides validated CAR constructs for CD19, CD20, and BCMA—three of the most clinically relevant antigens for B-cell malignancies and multiple myeloma. High-affinity binder generation is included with all target-specific services, as well as CAR expression validation, cytokine profiling, and cytotoxicity assays to deliver robust preclinical characterization.
* BCMA (B-cell maturation antigen): A major target in multiple myeloma, Creative Biolabs offers optimized CAR constructs with increased persistence and tumor-cytotoxicity.
* CD19: Found widely expressed across B-cell leukemias and lymphomas, CD19-targeted CAR-T therapies remain a cornerstone of hematologic cancer treatment.
* CD20: With over 90% expression across B-cell lymphomas, CD20-targeted CARs represent a complement or alternative to CD19-targeted therapies.

"Our CAR-T design platform's compatibility with early-stage product development and cross-functional testing makes us a go-to partner for biotech organizations, academic institutions, and manufacturing partners who require plug-and-play solutions for exploratory or pre-commercial programs," said the scientist.

Creative Biolabs has already enabled numerous successful collaborations in North America, Europe, and Asia, offering custom construct design for both discovery and translational programs in the area of immunoengineering. This company is still investing in research and development to further advance its capabilities toward multi-specific CAR formats, co-stimulatory logic, and payload integration for expanding design space.

For collaboration prospects, please visit https://www.creative-biolabs.com/car-t/.

About Creative Biolabs
With over 20 years of experience in antibody engineering and cell therapy development, Creative Biolabs has been a key partner for multinational pharmaceutical companies, biotech companies, and research institutions.

Candy Swift
Creative Biolabs
+ +1 631-830-6441
marketing@creative-biolabs.com